Last updated: February 14, 2026
Overview
NDC 50268-0198 corresponds to Veklury (remdesivir), an antiviral drug approved by the FDA for the treatment of COVID-19. Since its initial emergency use authorization, Veklury has become a standard therapy for hospitalized COVID-19 patients. The market landscape has evolved with increased vaccination rates and the development of new therapeutics, influencing sales and pricing strategies.
Market Size and Demand Drivers
Global COVID-19 Treatment Market
- Expected CAGR from 2022 to 2027: approximately 12.8% (source: MarketsandMarkets).
- Total COVID-19 antiviral market value (2022): estimated at $15 billion.
- Veklury's contribution: estimated to account for 55-65% of antiviral sales in U.S. hospitals as of 2022.
Key Demand Factors
- Pandemic progression and global infection rates.
- Regulatory approvals for use in outpatient settings and for emerging variants.
- Institutional adoption patterns, especially in hospitals and clinics.
- Competition from emerging oral antivirals (e.g., Paxlovid, Lagevrio).
Market Penetration
Veklury remains a first-choice antiviral in several countries, especially where safety profiles and efficacy are well-established. Its use in early-stage outpatient treatment is limited, impacting overall volume growth.
Competitive Landscape
- Main competitors: Paxlovid (Pfizer), Lagevrio (Eli Lilly).
- Market dynamics: Shift toward oral agents reduces IV antiviral demand in outpatient settings.
- Impact on Veklury: Slower growth in the outpatient market but sustained inpatient use due to proven efficacy and safety in severe cases.
Pricing Trends
Historical Pricing
- List price (2021): approximately $2,340 per 100 mg vial (average wholesale price).
- Typical course of treatment: 6 vials over 5-10 days, averaging ~$14,000 per patient.
Pricing Strategies
- Commercial payers: negotiate discounts reducing the average price by 15-25%.
- Medicare/Medicaid: reimbursement averaged around $3,000-6,000 per course depending on administrative margins.
- Contractual discounts and rebates: significant, no publicly disclosed exact figures.
Market Factors Influencing Price
- Cost of manufacturing and distribution.
- Competitive pressure from oral antivirals.
- Government procurement policies, especially in the U.S., including the Department of Health and Human Services (HHS) purchasing agreements.
Price Projections (Next 2-5 Years)
| Year |
Projected Average Price per Course |
Key Drivers |
| 2023 |
$13,000 - $14,000 |
Existing prices maintained, slight discounts due to negotiations |
| 2024 |
$12,000 - $13,000 |
Increased competition, potential volume growth |
| 2025 |
$10,000 - $12,000 |
Market saturation, better outpatient options |
| 2026 |
$8,000 - $10,000 |
Growth in oral antiviral use, emphasis on outpatient treatment |
| 2027 |
$6,000 - $8,000 |
Potential decline in inpatient demand, government negotiations |
Assumptions:
- Continued reliance on parenteral administration constrains price drops.
- Emergence of competitive oral therapies limits market share growth, pressuring prices downward.
- Governments and payers push for cost containment, increasing discounting.
Regulatory and Policy Impact
- EBM guideline updates influence prescribing, with more outpatient options reducing inpatient demand.
- Federal procurement policies may maintain or lower prices via bulk purchases.
- Patent status and potential biosimilar or generic entry are unlikely before 2030.
Market Risks
- New oral agents gaining regulatory approval and market share.
- Changes in COVID-19 epidemiology affecting demand.
- Price reductions driven by payer negotiations and government policies.
Summary
Veklury maintains a significant position within hospitalized COVID-19 treatment, with projected prices declining gradually over the next five years due to increased competition and shifting treatment paradigms. The current average course price (~$14,000) is expected to decrease to around $6,000-$8,000 by 2027.
Key Takeaways
- The global COVID-19 antiviral market is expanding but faces increasing competition.
- Veklury's inpatient usage sustains revenue but faces pressure from oral therapies.
- Price per treatment course is projected to decline approximately 50% from current levels within five years.
- Government negotiations and bulk procurement will influence final pricing.
- Long-term market share depends on the emergence of alternative treatments and updates in clinical guidelines.
FAQs
-
How does the market for remdesivir compare to oral COVID-19 antivirals?
Oral antivirals such as Paxlovid have captured a substantial share of outpatient treatment, reducing demand for IV therapies like remdesivir in early-stage disease.
-
What regional trends influence Veklury's price?
Pricing varies by region, driven by local healthcare policies, negotiation power, and market penetration, with the U.S. typically facing higher prices due to less price regulation.
-
Are biosimilars or generics expected for remdesivir?
No biosimilar or generic versions are projected before 2030 due to patent protections and manufacturing complexities.
-
What impact will new variants have on Veklury demand?
Variants with different pathogenic profiles could alter demand patterns, but remdesivir’s broad efficacy against multiple strains supports ongoing use.
-
How will government procurement strategies affect future prices?
Bulk purchasing and contractual discounts can lower the effective price paid by public payers, potentially accelerating downward price trends.
References
[1] MarketsandMarkets. COVID-19 Antiviral Market, 2022-2027.
[2] FDA. Remdesivir (Veklury) approval and usage guidelines.
[3] IQVIA. US Pharmaceutical Pricing Trends, 2022.
[4] HHS. COVID-19 Therapeutic Procurement Data, 2022.
